The safety and efficacy of Sclerosing Foam on treating Venous leg ulcers: protocol for systematic review and meta analysis

Fan, Weijing; Xiao, Yang; Yang, Baoxue; Fu, Changgeng; Huang, Renyan; Xv, Feng; Liu, Guobin

doi:10.37766/inplasy2020.7.0003

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venous leg ulcers (VLUs) occur with increasing prevalence, and their prevalence in the United States is approximately 10% to 30%. 1,2 The available treatment options on VLUs include compression therapy, surgical debridement, hyperbaric oxygen therapy, growth factors, skin grafting, and oral drugs. 2 However, VLUs still cannot be solved successfully.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 The available treatment options on VLUs include compression therapy, surgical debridement, hyperbaric oxygen therapy, growth factors, skin grafting, and oral drugs. 2 However, VLUs still cannot be solved successfully. VLUs result from a complex process secondary to increased pressure (venous hypertension) and inflammation within the venous circulation, vein wall, and valve leaflet with extravasation of inflammatory cells and molecules into the interstitium.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Pentoxifylline for Venous Leg Ulcers: An Updated Meta-Analysis

Sun

Gao

et al. 2021

The International Journal of Lower Extremity Wounds

View full text Add to dashboard Cite

The venous leg ulcers are debilitating, painful, and often unresponsive to advanced dressing treatments, so drugs used locally and systematically are essential adjuvant therapy—pentoxifylline (PTX) whose anti-inflammatory effects may offer a promising avenue to treat venous leg ulcers. However, the current results are controversial. To further evaluate the efficacy and safety of PTX, we performed an updated meta-analysis of randomized placebo-controlled trials of PTX in the treatment of venous leg ulcers. We systematically searched multiple electronic databases PubMed, Web of Science, Embase, the Cochrane Library, the Cochrane Central Register of Controlled Trials, China Science and Technology Journal Database, WanFang Data, China National Knowledge Infrastructure, and the Chinese Biomedical Literature Database to identify eligible studies. Randomized clinical trials of pentoxifylline versus placebo treatment in patients with venous leg ulcers were considered for inclusion. The primary outcomes included ulcer healing rate and the incidence of adverse events after treatment. The secondary outcomes were the ulcer significant improvement (the ulcer size shrank by more than 60% after treatment) rate, mean duration of complete wound healing and changes in mean ulcer size. A meta-analysis and qualitative analysis were conducted to estimate endpoints. A total of 13 randomized clinical trials, including 921 individuals, were finally included. Compared with placebo, pentoxifylline significantly improved the ulcer healing rate (RR = 1.59, 95%CI 1.22 to 2.07, P < .001) and significant improvement rate (RR = 2.36, 95%CI 1.31 to 4.24, P = .004) while increased the incidence of gastrointestinal disturbances (RR = 2.29, 95%CI 1.04 to 5.03, P = .04) at the same time. Moreover, pentoxifylline also shortened mean duration of complete wound healing ( P = .007) and shrank ulcer size ( P = .02). Currently available evidence suggests that pentoxifylline could help venous leg ulcers heal more quickly and effectively. However, the evidence is insufficient to prove the results due to moderate-certainty evidence. Large-scale, well-designed randomized clinical trials are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%